head_ocd Columbia University Medical Center Center for OCD and Related Disorders


ADULT       CHILD/ADOLESCENT       ONLINE

We are currently recruiting participants for a wide range of research studies! Our research work is funded in large part by the National Institutes of Health and by private foundations. If you are interested in participating in one of our research studies, please call (646) 774-7000 (or one of the study specific numbers listed below). We will offer you a confidential screening and evaluation to determine whether you are eligible for one of our studies. Any treatment you receive as part of your study participation is provided at no cost to you.
OCD Treatment with Cognitive Behavioral Therapy

Attaining and Maintaining Wellness in OCD (IRB# 6628)

SEE OUR FLYER HERE! 
  • Are you between the ages of 18 - 75?
  • Are you taking one of the following medications for obsessive- compulsive disorder (OCD)?
    • Clomipramine (Anafranil)
    • Fluoxetine (Prozac)
    • Fluvoxamine (Luvox)
    • Sertraline (Zoloft)
    • Paroxetine (Paxil)
    • Citalopram (Celexa)
    • Escitalopram (Lexapro)
  • Are you still having bothersome symptoms?
  • Are you interested in receiving no-cost therapy treatment that may improve your symptoms such that you may be able to stop taking your medication?
If you answered "yes" to all four questions, you may be eligible for treatment as part of our research study “Attaining and Maintaining Wellness in OCD.” Doctors often begin OCD treatment by giving patients medications such as Anafranil, Prozac, Luvox, Zoloft, Paxil, Celexa, or Lexapro. For many patients these medications are helpful, but do not provide adequate relief of OCD symptoms.  For these patients, there is a need for additional treatment options. This study investigates add-on treatments for people taking medications for their OCD, but still in need of more help.

Eligible participants initially remain on a stable dose of their OCD medication and will receive cognitive behavioral therapy consisting of Exposure and Ritual Prevention (EX/RP) twice a week for up to 12 weeks as additional treatment. Participants who become well (with only minimal to mild OCD symptoms) after the EX/RP will be randomly assigned (assigned by chance) to either continue their medication or begin to taper off their medication and have it gradually replaced with a placebo (sugar pill).

All patients will be carefully monitored throughout the study for 24 weeks. The goal of the study is to understand whether patients with OCD on Serotonin Reuptake Inhibitors (SRIs) who achieve wellness from EX/RP can safely discontinue their medication.
This study, funded by the National Institute of Mental Health, is a collaboration between Dr. Blair Simpson from Columbia University-New York State Psychiatric Institute and Dr. Edna Foa from the University of Pennsylvania.

For more information about participation, please contact Marissa Schwartz at (646)774-8062 or see our study specific website at www.ocdtreatmentstudy.com.


                                        Control and Reward Circuits in OCD (IRB#7000)


1.    Are you between the ages of 18 – 55?
2.    Do you have bothersome OCD symptoms?
3.    Are you not taking any psychiatric medications?
4.    Are you interested in receiving no-cost therapy treatment that may improve your symptoms?

If you answered "yes" to all four questions, you may be eligible for treatment as part of our research study “Control and Reward Circuits in OCD.” Eligible participants will be asked questions about their symptoms, perform tasks on a computer, and receive 17 sessions of cognitive behavioral therapy consisting of Exposure and Ritual Prevention (EX/RP). You will receive a brain scan using Magnetic Resonance Imaging (MRI) both before and after therapy. The purpose of this study is to assess whether therapy treatment with EX/RP changes the brain.

For more information about participating, please call Olivia Pascucci at (646) 774-8064.



Internet Based Treatment for OCD (iCBT) (IRB# 6837)

This study is for New York and New Jersey state residents who are having trouble with their OCD symptoms and would be interested in participating in a research study to test the effectiveness of a ten week therapist-supported online treatment.
   
Online treatment will be provided at no cost. The goal of this study is to help participants improve the severity of their OCD through online cognitive behavioral therapy (CBT), which includes evidence -based exposure and response prevention (EX/RP) techniques. One in-person evaluation at the Columbia University Medical Center is required for the program, and the rest of the treatment will be completed from the convenience of your own computer. Participants will have 10 weeks to complete 10 online treatment modules, guided by a study therapist, who will be available to them every step of the way via the online treatment platform. The online therapy modules will help you learn about your OCD and guide you through a treatment program that is tailored to fit your needs.

For more information about participating, please call Olivia Pascucci at (646) 774-8064.

Understanding the Brain Basis of OCD

        

We are currently investigating the brain mechanisms underlying the symptoms of OCD.  The studies listed below use cutting edge techniques to investigate the neurochemistry of the brain, the functioning of brain circuits, and the way the brain processes information.  
 
If you are over 18 and NOT currently on psychiatric medications, you may be eligible to participate in one or more of these studies. All participants are compensated for their time (up to $285 per study) depending on the specific study. To schedule a confidential screening please contact the center at (646)774-7000.
 

fMRI: Studies of the Brain in Health and Illness

(IRB# 6159)

This study uses functional magnetic resonance imaging (fMRI) to measure brain activity across different brain regions while participants are performing a series of computer tasks. Participants are also asked to complete neuropsychological tasks and clinical evaluations. Eligible participants must be between the ages of 18 - 45.

Neurobehavioral Tasks in OCD and Related Disorders (IRB# 6430)

This study uses different neurobehavioral tasks and questionnaires to measure one's stress reactivity, startle reflexes, and preferences. To be eligible you must be between the ages of 18 - 50.

Hoarding Disorder


Treatment Acceptability for Hoarding Disorder (IRB# 6677)


1.    Do you have trouble with clutter, excessive collecting, or hoarding?
2.    Can you tell us what type of treatments and services you find acceptable?
   
    If so, please participate in an anonymous online survey to help us understand what kinds of treatments and services are acceptable to individuals who engage in hoarding behaviors, such as difficulty discarding or parting with possessions, excessive acquiring, and clutter in their home. Participation is limited to once per person and it takes approximately 30 minutes to complete. After completing the survey, you can enter for a chance to win a $100 Amazon.com gift card.

Click here to participate in the survey.

For more information related to Hoarding Disorder treatment and research, please call Jordana Zwerling at (646) 774-8128 or visit the Columbia Hoarding Research Program website: http://columbiapsychiatry.org/hoarding


OCD Treatment with Novel Medications


Extending Ketamine's Effects in OCD with Exposure and Response Prevention (EX/RP) (IRB# 6811)

This study investigates if a single dose of IV ketamine can rapidly improve OCD symptoms and whether these effect can be maintained with a condensed course of a type of Cognitive Behavioral Therapy called exposure and response prevention (EX/RP). You will be compensated for your time and travel. Participants must be between the ages of 18-55. For more information, please contact the study coordinator: Jordana Zwerling at (646)774-8118.


Randomized Controlled Trial of Intranasal Ketamine vs. Intranasal Midazolam in Individuals with OCD (IRB# 6952)

The present study, will test if intranasal ketamine is feasible to use and can reduce OCD symptoms significantly more than a comparison medication called midazolam. Therefore, you may or may not receive ketamine as part of this study. Results from this study will allow doctors and researchers to better understand if you and others with OCD may respond to this class of medications. You will be compensated for your time and travel. Participants must be between the ages of 18-55. For more information, please contact the study coordinator: Jordana Zwerling at (646) 774-8118.



Novel Medication Study: GLYX-13 in OCD (IRB# 6986)

This research study tests whether GLYX-13 – an experimental drug that acts on a brain receptor called NMDA - can decrease symptoms of OCD within hours. This is not a treatment study. Results from this study will allow doctors and researchers to better understand if you and others with OCD may respond to a class of medications that target the NMDA brain receptor. You will be compensated for your time and travel. Participants must be between the ages of 18 - 55. For more information about participation, or to schedule a confidential phone screening, please contact the study coordinator: Jordana Zwerling at (646)774-8118


 

Under 18 Years of Age? Opportunities for Child & Adolescent Treatment and Studies

 

 Clinical Trial of Minocycline in Pediatric OCD (IRB#6574)

1.    Is your child taking one of the following medications for OCD?
 Clomipramin (Anafranil)
 Fluoxetine (Prozac)
     Fluvoxamine (Luvox)
 Sertraline (Zoloft)
 Paroxetine (Paxil)
 Citalopram (Celexa)
 Escitalopram (Lexapro)
2.    Does your child still have bothersome symptoms?
3.    Is your child between the ages of 8-20?
4.    Are you interested in receiving no-cost cutting edge treatment for your child?

     If you answered “yes” to the previous questions, your child may be eligible for treatment as part of a research program at Columbia University/ New York State Psychiatric Institute.

     During the 12 week study period, your child will continue to take the SRI s/he is currently taking. Your child will also be given another pill to take which will be either minocycline or a placebo pill ("sugar pill," with no active medication in it). There is a two out of three chance that your child will receive minocycline instead of placebo. You, your child, and the study doctor will not know whether your child is receiving minocycline or placebo until after the study is over, but the information will be available in case of a medical emergency. After the study period, follow-up care including medication management will be provided for three additional months at no cost to you.

For more information about participating, please contact Prerna Martin at (646) 774-5793.

More Research/Treatment Information for Children & Adolescents

The Columbia University Clinic for Anxiety & Related Disorders (CUCARD) for Children & Adolescents

The Children's Day Unit at Columbia University College of Physicians and Surgeons